NICE Approves Palbociclib Combo for HR+ Advanced Breast Cancer

December 2, 2019 – The UK National Institute for Health and Care Excellence (NICE) has approved palbociclib in combination with fulvestrant for the treatment of female patients with hormone receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy. The approval, which allows the combination to be available on the National Health Service (NHS) via the Cancer Drugs Fund (CDF), is based on … (leggi tutto)